| Business Summary | | Medichem
Life
Sciences,
Inc.
is
a
drug
discovery
technology
and
services
company
that
offers
a
broad
range
of
integrated
chemistry
research
and
development
capabilities
to
pharmaceutical
and
biotechnology
companies.
The
Company
offers
chemistry
services
that
span
the
entire
drug
development
spectrum,
from
early
stage
discovery
technologies
and
services
up
until
a
potential
drug
enters
clinical
testing.
Medichem
has
developed
proprietary
platform
technologies
in
the
areas
of
proteomics,
biocatalysis,
chiral
chemistry
and
automated
process
research.
These
technologies
utilize
automation
and
optimization
to
compress
the
drug
discovery
process
timeline
and
are
adaptable
to
multiple
customer
applications. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MediChem
Life
Sciences,
Inc.
is
a
drug
discovery
technology
and
services
company
that
offers
a
range
of
integrated
chemistry
R&D
capabilities
to
pharmaceutical
and
biotechnology
companies.
For
the
six
months
ended
6/30/01,
revenues
rose
21%
to
$10.8
million.
Net
loss
applicable
to
Common
increased
89%
to
$5.7
million.
Results
reflect
higher
contract
revenues
due
to
acquisitions
and
sales
growth,
offset
by
increased
depreciation
and
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Flavin, Ph.D., 45 Chairman,
Pres, CEO | $184K | Lance Stewart, Ph.D., 36 Pres--Emerald
BioStructures | -- | R. Richard Wieland II, 56 Exec.
VP, CFO | 150K | John Flavin, 32 Exec.
VP, COO, Director | 154K | Jeffrey Whitnell, 45 VP-Fin.,
Treasurer | 139K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|